Skip to content
[P]pubcas
Independent chemical reference Compare
Chemical substance record

Risperidone

106266-06-2C23H27FN4O2410.493 g/mol

A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2. — ChEBI

Safety references

Safety documents & references

Supplier matching matters

Find the safety document for your specific supplier, product number and grade.

Find a product-specific SDS

Safety guides and government classification records are not a manufacturer’s SDS. Match supplier, product number, concentration, physical form, region and revision before using a document.

Identity & molecular properties

Source-linked values
CAS number106266-06-2ChEBI ↗
Molecular formulaC23H27FN4O2ChEBI ↗
Molar mass410.493 g/molChEBI ↗
Monoisotopic mass410.2118 DaChEBI ↗
Formal charge0ChEBI ↗
ChEBI identifierCHEBI:8871ChEBI ↗

Cross-source molecular data

PubChem
Molar mass410.5 g/molPubChem ↗
Exact mass410.21180428 DaPubChem ↗
Computed XLogP2.7PubChem ↗
Topological polar surface area (Ų)61.9PubChem ↗
H-bond donors0PubChem ↗
H-bond acceptors6PubChem ↗
Rotatable bonds4PubChem ↗

PubChem computed values are shown separately from the ChEBI record. An exact InChIKey match was used to connect the records. Molecular descriptors do not describe a supplied product’s purity, particle size or performance.

Names & structural identifiers

Copy any identifier
risperidone
3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
RAPZEAPATHNIPO-UHFFFAOYSA-N
Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3

Names & synonyms

3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-oneRisperdalrisperidonarisperidonumRisperinRispoleptRispolinSequinan

Names are supplied by ChEBI. Trade names and related synonyms may describe a broader product context.

Classification & relationships

ChEBI ontology

Roles recorded in ChEBI

antidepressantpsychotropic druganxiolytic drugalpha-adrenergic antagonistH1-receptor antagonistserotonergic antagonistdopaminergic antagonistsecond generation antipsychoticEC 3.4.21.26 (prolyl oligopeptidase) inhibitor

Database role annotations describe reported biological or chemical roles; they are not product approvals or recommendations for use.

Mass ↔ amount of substance

Calculated from sourced mass
Equivalent amount
0.0024361 mol

Uses 410.493 g/mol from ChEBI. Assumes the substance described by this record; no purity or concentration correction is applied.

Elemental composition

Theoretical mass fractions
C
Carbon · 23 atoms
67.30%
N
Nitrogen · 4 atoms
13.65%
O
Oxygen · 2 atoms
7.80%
H
Hydrogen · 27 atoms
6.63%
F
Fluorine · 1 atom
4.63%

Calculated theoretical mass fractions from the reported formula and PubChem periodic-table atomic masses. These are not assay or purity results.

Research & patent references

Selected source associations
Acute and long-term treatment of catatonia with risperidone. ↗Pharmacopsychiatry · 2001 Jan · PMID 11229618
An evaluation of risperidone drug interactions. ↗Journal of clinical psychopharmacology · 2001 Aug · PMID 11476125
EP196132 · Patent reference ↗Patent cross-reference supplied by ChEBI. Association alone does not establish claim scope.
US4804663 · Patent reference ↗Patent cross-reference supplied by ChEBI. Association alone does not establish claim scope.

Sources & record history

Checked 27 Sep 2026
EMBL-EBI ChEBI · CHEBI:8871

Release 255, 9 September 2026. ChEBI three-star (manually annotated) source entry. View original record ↗ · CC BY 4.0

NCBI PubChem · CID 5073 · retrieved 2026-09-27

PubCAS formats source data, connects references and computes explicitly labelled conversions. CAS cross-references are supplied by ChEBI; they do not constitute CAS verification or endorsement.